Exploring early signs of progression in multiple sclerosis patients
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
This study is trying to find early signs of progression in people with relapsing multiple sclerosis by using different tests and scans to see if they can spot changes that aren't usually noticed.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Brugmann University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT05941975 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients diagnosed with relapsing multiple sclerosis (RMS) to explore subtle signs of disease progression using a multimodal approach. It employs various diagnostic tools, including visual evoked potentials, somatosensory evoked potentials, transcranial magnetic motor evoked potentials, advanced MRI techniques, and blood tests for neurofilament light chain. The goal is to identify early indicators of progression that may not be apparent through traditional assessments. By analyzing data from multiple evaluations over time, the study aims to enhance understanding of disease dynamics in RMS.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of relapsing multiple sclerosis who have had at least three functional evaluations over a minimum of 12 months.
Not a fit: Patients who cannot undergo the required paraclinical tests due to contraindications will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of disease progression in multiple sclerosis, allowing for timely interventions.
How similar studies have performed: While the concept of silent progression in multiple sclerosis is gaining attention, this specific multimodal approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients ≥ 18-year-old with diagnosis of RMS according to 2017 McDonald diagnostic criteria 2. Availability in the functional outcome database of at least 3 time-point complete evaluations with a time frame from the first to the last evaluation of minimum 12 months 3. Most recent functional outcome evaluation within 12 months of enrollment 4. Availability of follow-up MRI data during the observational period Exclusion Criteria: a) Contraindication to one or more of the paraclinical tests of the prospective multimodal evaluation
Where this trial is running
Brussels
- CHU Brugmann — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Vito Tota
- Email: Vito.TOTA@chu-brugmann.be
- Phone: 3224772446
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.